University of Michigan, Ann Arbor, MI
Steven J. Katz, Monica Morrow, Allison W. Kurian
Background: Increasing use of germline genetic testing may have unintended consequences on breast cancer treatment. We do not know whether treatment deviates from guidelines for women with pathogenic variants (PV) in cancer susceptibility genes. Methods: SEER data for all women aged ≥20 years, diagnosed with breast cancer in 2014-15 and reported to Georgia and California registries (N=77,588) by December 1, 2016 were linked to germline genetic testing results from 4 laboratories that did nearly all clinical testing. We examined first course of therapy of stage <IV patients who linked to a genetic test: bilateral mastectomy (BLM) in candidates for surgery (unilateral, stages 0-III); post-lumpectomy radiation in those with an indication (all but age ≥70, stage I, hormone receptor (HR)-positive and HER2-negative); and chemotherapy in those without definitive indication (stage I-II, HR-positive, HER2-negative and 21-gene recurrence score <30). We report the percent treated based on multivariable modeling, adjusted for age, race, stage, grade, insurance and socioeconomic status. Results: The table shows that 9% of patients who linked to a genetic test result had a PV (N=1,283). Compared to women with negative results, those with BRCA1/2 PVs were more likely to receive BLM, more likely to receive chemotherapy without definitive indication, and less likely to receive indicated radiation as initial treatment. Lower-magnitude effects were seen with other PVs but not variants of uncertain significance (VUS). Conclusions: In a population-based setting, women with PVs in BRCA1/2 or other cancer susceptibility genes may have higher risk of receiving locoregional and systemic treatment that does not follow guidelines.
Test Results (mutually exclusive) | Treatment Use |
||
---|---|---|---|
BLM N=10,144 % (95% CI) |
Radiation N=4,575 % (95% CI) |
Chemotherapy N=5,504 % (95% CI) |
|
Negative N=10,418 | 23.0 (22.0-24.0) | 74.5 (73.1–75.9) | 19.2 (18.1-20.3) |
VUS N=2,539 | 24.6 (22.5-26.7) | 74.2 (71.2–77.2) | 18.4 (16.1-20.9) |
BRCA1/2 PV N=850 | 55.4 (51.0-59.9) | 48.0 (38.1–57.8) | 31.6 (26.7-36.6) |
Other PV* N=433 | 34.5 (28.9-40.1) | 68.1 (59.8–76.3) | 23.6 (17.8-29.4) |
*ATM, CHEK2, PALB2, NBN, TP53, BARD1 and others
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Genitourinary Cancers Symposium
First Author: Siqi Hu
2023 ASCO Annual Meeting
First Author: Nicole Casasanta
2024 ASCO Quality Care Symposium
First Author: Erin Aiello Bowles
2022 ASCO Annual Meeting
First Author: Marija Stojovska